The evolving role of cellular therapies and T-cell engagers in lymphoma

This VJHemOnc podcast explores emerging cellular therapies and T-cell engagers in non-Hodgkin lymphoma (NHL). Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, to discuss novel cellular therapy strategies, including NK-cell therapies, allogeneic CAR T-cells, and in vivo CAR approaches. The panel highlights early clinical data with the iPSC-derived NK-cell products FT516 and FT596, alongside evolving strategies to reduce CAR T-cell toxicity and improve access to cellular therapies. The podcast also features Loretta Nastoupil, MD, Southwest Oncology, Durango, CO, Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, and Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss the expanding role of T-cell engagers in follicular lymphoma and large B-cell lymphoma, including mosunetuzumab-based combinations and the growing number of frontline bispecific antibody trials in diffuse large B-cell lymphoma.